Indapta Therapeutics Presents Data Demonstrating Clinical Activity of its Allogeneic Natural Killer Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma

Data from ongoing Phase 1/2 trial presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

HOUSTON & SEATTLE--(BUSINESS WIRE)--Indapta Therapeutics, Inc., a privately held clinical stage biotechnology company developing next-generation differentiated immunotherapies for the treatment of cancer and autoimmune diseases, today announced the presentation of data highlighting the clinical activity of IDP-023, the Company’s allogeneic g-NK cell therapy, in patients with relapsed/refractory multiple myeloma. IDP-023 treatment was given as a standalone therapy and in combination with isatuximab, an anti-CD38 monoclonal antibody approved for the treatment of multiple myeloma.

“We are encouraged to observe this degree of clinical activity of IDP-023 alone and in combination with isatuximab,” said Dr. Mark Frohlich, CEO of Indapta. “This is particularly noteworthy given the extent of prior therapies and adverse prognostic features of the patients treated. We look forward to treating additional patients to better characterize the response proportion and durability of treatment effect.”

The data will be presented at the Society for Immunotherapy of Cancer (SITC) annual meeting, taking place November 7-9, 2025, in Washington, DC. The presentation (Abstract #1322), entitled “IDP-023 Allogeneic g-NK-cells +/- Anti-CD38 Monoclonal Antibody for the Treatment of Relapsed/Refractory Multiple Myeloma: Safety, Efficacy and Determination of Recommended Phase 2 Dose,” summarizes the data from the safety run-in of the Phase 1 trial as well as the initial cohort of patients treated with IDP-023 in combination with an anti-CD38 monoclonal antibody. Patients received one to three doses of IDP-023, with or without interleukin-2 (IL-2).

Key highlights from the data presentation include:

• Marked tumor reduction was observed in patients treated with IDP-023 alone and in combination with isatuximab.
• In patients treated with IDP-023 at the second dose level of 10 billion cells/dose in combination with isatuximab, confirmed responses were observed in 4 of 5 response evaluable patients. These patients were heavily pre-treated with high-risk and ultra high-risk cytogenetics.
  • Responses included a stringent complete response in a patient with extramedullary disease who experienced prior progression following treatment with both CAR-T and T-cell engager therapy.
  • A second cycle of IDP-023 in combination with isatuximab in select patients appeared to improve the depth and duration of response.
• Treatment was generally well-tolerated with no dose limiting toxicities. The most common adverse events were cytopenias related to the conditioning chemotherapy.

Indapta’s Proprietary g-NK Cell Therapy

Indapta’s universal, allogeneic NK cellular immunotherapy platform consists of a potent subset of naturally occurring NK cells, known as “g minus” NK cells, or “g-NK” cells. g‑NK cells arise from epigenetic changes resulting from exposure to cytomegalovirus (CMV). To generate IDP-023, Indapta preferentially expands g-NK cells from healthy donors, with low donor to donor variability. IDP-023 has several differentiated mechanisms of killing target cells without the need for genetic engineering, including highly robust antibody-dependent cell mediated cytotoxicity (ADCC), the targeting of HLA-E expressing cells via the NKG2C receptor, and the inherent anti-viral activity of g-NK cells.

Indapta’s g-NK can release dramatically more immune activating cytokines and cell-killing compounds than conventional NK cells. In preclinical studies, IDP-023 has demonstrated more potent and durable antitumor activity when combined with cancer targeting monoclonal antibodies as compared to conventional NK cells. (Bigley et al., Blood Advances 2021, https://doi.org/10.1182/bloodadvances.2020002440). g-NK cells in combination with a B cell targeting antibody can also deplete normal B cells from healthy donors or patients with autoimmune disease.

About Indapta Therapeutics

Indapta is a privately held company focused on developing and bringing to market a diverse pipeline of cellular immunotherapies to treat the still unmet medical needs of patients with blood and solid-tumor cancers as well as autoimmune diseases. The company’s proprietary robust platform of naturally occurring g-NK cells is specifically designed to create best-in-class, highly potent, more accessible, and scalable cell therapies. For more information, please visit www.indapta.com.